39 However, differences between armodafinil and placebo in terms of MWT assessments at timepoints later in the day (15:00, 17:00, and 19:00) did not reach statistical significance at the final visit in the individual studies. 36 , 37 Clinical condition measured using the Clinical Global Impression of Change (CGI-C) was a second primary endpoint in both of the studies that evaluated armodafinil in patients with ES associated with OSA.
1
—
—